The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
PSA response and early PSA progression evaluated in patients randomized in a phase III trial comparing androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in hormone-naive metastatic prostate cancer (GETUG-AFU 15/0403).
G. Gravis
No relevant relationships to disclose
K. Fizazi
Employment or Leadership Position - Sanofi
F. Joly
No relevant relationships to disclose
S. Oudard
Employment or Leadership Position - Sanofi
F. Priou
No relevant relationships to disclose
I. Latorzeff
No relevant relationships to disclose
R. Delva
No relevant relationships to disclose
B. Esterni
No relevant relationships to disclose
M. Habibian
No relevant relationships to disclose
M. Soulie
No relevant relationships to disclose